Strategies for MMP inhibition in cancer: innovations for the post-trial era.
about
Metalloproteinase inhibitors: status and scope from marine organismsA novel binding factor of 14-3-3beta functions as a transcriptional repressor and promotes anchorage-independent growth, tumorigenicity, and metastasisHuman polyserase-2, a novel enzyme with three tandem serine protease domains in a single polypeptide chainIdentification and characterization of human and mouse ovastacin: a novel metalloproteinase similar to hatching enzymes from arthropods, birds, amphibians, and fishThe structure and regulation of the human and mouse matrix metalloproteinase-21 gene and proteinA genomic analysis of rat proteases and protease inhibitorsMolecular mechanism of pancreatic tumor metastasis inhibition by Gd@C82(OH)22 and its implication for de novo design of nanomedicineInflammation and cancerProcessing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors42nd Annual Meeting of the American Society for Cell Biology, San Francisco, California, USA, 14-18 December 2002Charge-reversal nanoparticles: novel targeted drug delivery carriersThe Role of Matrix Metalloproteinases in Diabetic Wound Healing in relation to PhotobiomodulationRoles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic ApproachesPotential Effects of Pomegranate Polyphenols in Cancer Prevention and TherapyCandidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitorsCell-cell and cell-matrix dynamics in intraperitoneal cancer metastasisMatrix metalloproteinases in human spontaneous intracerebral hemorrhage: an updateThe relationship between the MMP system, adrenoceptors and phosphoprotein phosphatasesSelective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal CancerSurface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic targetThe structure of the catalytic domain of Tannerella forsythia karilysin reveals it is a bacterial xenologue of animal matrix metalloproteinasesMetalloprotein–Inhibitor Binding: Human Carbonic Anhydrase II as a Model for Probing Metal–Ligand Interactions in a Metalloprotein Active SiteMatrix metalloproteinases in inflammatory bowel disease: an updateActive stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinaseUtilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding theThe intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modelingLGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathwayFunctional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasivenessBiochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decadeTumor cell-mediated induction of the stromal factor stromelysin-3 requires heterotypic cell contact-dependent activation of specific protein kinase C isoformsMatrilysin (MMP-7) is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosisPre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screeningTumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancerA phage display selected 7-mer peptide inhibitor of the Tannerella forsythia metalloprotease-like enzyme Karilysin can be truncated to Ser-Trp-Phe-ProMetalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulationSynthesis, characterization and in vitro study of biocompatible cinnamaldehyde functionalized magnetite nanoparticles (CPGF Nps) for hyperthermia and drug delivery applications in breast cancerInhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte CulturesMMpI: A WideRange of Available Compounds of Matrix Metalloproteinase InhibitorsCross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivoIdentification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain
P2860
Q21296828-5522995F-2987-4878-9971-9C68B2782AA8Q24310237-954EE7DC-C526-4732-B623-FE6646D92B96Q24313309-744184D6-5E35-4048-B421-1064F7375B6FQ24337050-774E7879-A3D9-482F-A2CF-405F7F3D2481Q24529965-F259607C-BC5E-445A-BACD-6E03FF18230DQ24597956-F5C9E3BA-3760-48BA-8179-CE32B502206FQ24633644-8B6D4CFF-4746-40A6-BADF-FD29D7E6B627Q24649640-0747B93C-AB09-4000-957D-27F101EB942FQ24678647-F51A53F3-9202-4C50-A52D-C7216C6638F4Q24803561-578DEE6D-A419-4E88-B60F-43B076EC7F98Q26740583-E37695ED-413F-4EE0-94B3-C46F98A9F334Q26744533-31A0B1DA-D74B-4721-B606-E779FA58EAF8Q26752576-3B90E013-9F3E-4960-9AC6-8C1AA2F0AFA4Q26800877-B97B69CF-17DA-4D4A-89BC-0893AF63B974Q26830522-CA1A2F61-97BD-4881-8074-2A2F2AAFEC8AQ26851836-DBBAB1C6-3060-4127-A092-5CE8936939D6Q27001044-3F90E44C-C4E5-4E4E-9992-2F0F7D32D8A5Q27003263-375C5BAF-76CB-4984-AF55-03903633E668Q27306938-FD0912C1-B75D-49F9-97B5-A4BA388839F7Q27311163-255E6D5C-E53D-4079-B3CD-55E943B2A92CQ27666329-A9003EC9-6D41-498F-81D5-B92D4A38E02DQ27678293-1FFB2FED-AB14-402A-BC30-6DE7409966F2Q28080664-1368DA85-2B1C-44C0-886B-E9949FCBF437Q28185337-B6F51B3B-B15E-4605-9EBF-E400BAA1B991Q28206603-0AEB9272-359A-4F24-80C5-641AF973119DQ28207951-052D0930-A600-40C6-803B-C6E669EB35F2Q28253059-578B2EA8-29CB-4258-8F99-BF635D5BE487Q28261997-FBFD0815-4533-4C60-80DC-5776C6125101Q28288148-F88AE1C8-A4FC-46C2-889E-FA27828C4F03Q28290155-51BD151E-D4D9-43E4-A3B6-775990C245A4Q28306296-0C12067C-9346-4E7C-AE37-B83E27B5AFE8Q28394124-00BEECBD-C16D-4B66-92F1-E8F42E66101CQ28483867-D88CDBC4-3938-4F94-8E93-10F80E566EF1Q28484676-A89D6392-B595-46A2-A7BF-FF1BA02FD621Q28512433-20E94C81-3FC9-4828-89BB-7154171949B9Q28543393-594E60B1-002F-471F-9B9B-23A07C044487Q28547985-577FE3E6-892B-4CAC-AB3B-ED7C90FF5BE0Q28553432-53E55DE5-745A-4EAE-987E-BBA8C849EF19Q28576485-266CEEA6-ED16-40F1-9C06-694D9ED099C8Q28591587-40E503B4-4CD2-43D8-8B24-153B86D6D179
P2860
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@ast
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@en
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@nl
type
label
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@ast
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@en
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@nl
prefLabel
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@ast
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@en
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@nl
P356
P1476
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
@en
P2093
Christopher Mark Overall
P2888
P304
P356
10.1038/NRC884
P407
P577
2002-09-01T00:00:00Z
P5875
P6179
1004342262